During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...

Finally, let's turn to the New England Journal of Medicine. Speaking of closing the loop, this is the final analysis of overall survival with pembrolizumab in early-stage triple-negative breast cancer ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...